Designing transformative clinical trials in the cancer genome era

Journal of Clinical Oncology

Volumn 31, Issue 15, 2013, Pages 1834-1841

  Sleijfer, Stefan ^a   Bogaerts, Jan ^b   Siu, Lillian L ^c  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); CLONAL EVOLUTION; COHORT ANALYSIS; HISTOLOGY; HUMAN; LONGITUDINAL STUDY; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; STUDY DESIGN; DRUG DESIGN; GENETICS; GENOMICS; METHODOLOGY; NEOPLASM; STANDARD; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; GENOMICS; HUMANS; NEOPLASMS; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880502601     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.3639     Document Type: Review

References (35)

1. Goldstraw P, Ball D, Jett JR, et al: Non-small-cell lung cancer. Lancet 378:1727-1740, 2011
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. Maitournam A, Simon R: On the efficiency of targeted clinical trials. Stat Med 24:329-339, 2005
4. Sposto R, Stram DO: A strategic view of randomized trial design in low-incidence paediatric cancer. Stat Med 18:1183-1197, 1999
5. Deley MC, Ballman KV, Marandet J, et al: Taking the long view: How to design a series of Phase III trials to maximize cumulative therapeutic benefit. Clin Trials 9:283-292, 2012
6. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
7. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
8. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-2011, 2003
9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
10. Kwak EL, Bang YJ, Camidge DR, et al: Ana-plastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
11. Rini BI: New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16:1348-1354, 2010
12. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99:1036-1043, 2007
13. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
14. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:269s, 2010 (suppl; abstr 3534)
15. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012
16. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607, 2012
17. Tentler JJ, Tan AC, Weekes CD, et al: Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338-350, 2012
18. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
19. Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972-2977, 2011
20. Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774, 2006
21. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743-1749, 2006
22. Antonescu CR, Besmer P, Guo T, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-4190, 2005
23. Hall JA, Daidone MG, Peters GJ, et al: Integrating collection of biospecimens in clinical trials: The approach of the European Organization for Research and Treatment of Cancer. Biopreserv Bio-bank 9:181-186, 2011
24. Dancey JE, Dobbin KK, Groshen S, et al: Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16:1745-1755, 2010
25. Wellcome Trust Sanger Institute: Frequency of PIK3CA mutations based on primary tissue type. http://cancer.sanger.ac.uk/cosmic/gene/analysis?lnPIK3CA#histo
26. Rodón J, Saura C, Dienstmann R, et al: Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 9:359-366, 2012
27. Tran B, Brown AM, Bedard PL, et al: Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. Int J Cancer 132:1547-1555, 2013
28. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
29. Berry DA, Herbst RS, Rubin EH: Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: Design strategies for personalized therapy trials. Clin Cancer Res 18:638-644, 2012
30. Esserman LJ, Berry DA, DeMichele A, et al: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL—CALGB 150007/ 150012, ACRIN 6657. J Clin Oncol 30:3242-3249, 2012
31. Moretti S, De Falco V, Tamburrino A, et al: Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim Biophys Acta 1793:1634-1645, 2009
32. Sen B, Peng S, Tang X, et al: Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 4:136ra70, 2012
33. Stewart DJ, Kurzrock R: Cancer: The road to Amiens. J Clin Oncol 27:328-333, 2009
34. Hoering A, Leblanc M, Crowley JJ: Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 14:4358-4367, 2008
35. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000